Stock Market & Financial Investment News

News For PFE;ENDP From The Last 14 Days Check below for free stories on PFE;ENDP the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 22, 2013 08:59 EDT PFE On The Fly: Pre-market Movers Subscribe for More Information 08:06 EDT PFE Zoetis comments on Pfizer’s split-off plans for remaining interest Subscribe for More Information 08:04 EDT PFE Pfizer announces plan to split-off remainder of Zoetis Subscribe for More Information 08:02 EDT PFE Pfizer announces plan to split-off remainder of Zoetis Subscribe for More Information May 21, 2013 07:16 EDT PFE Pfizer management to meet with Leerink Subscribe for More Information May 20, 2013 17:04 EDT PFE Pfizer discontinues phase 3 study of inotuzumab ozogamicin Subscribe for More Information May 17, 2013 11:53 EDT ENDP Options with decreasing implied volatility: SGMO ARNA CSC ENDP Subscribe for More Information May 16, 2013 10:03 EDT ENDP On The Fly: Analyst Upgrade Summary Subscribe for More Information 08:55 EDT PFE BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call Subscribe for More Information 08:27 EDT ENDP Endo Health upgraded to Buy from Neutral at Buckingham Buckingham upgraded Endo Health based on attractive risk/reward and expectations for a more detailed strategy from the new CEO, maybe by Q2 results. Price target remains $41. May 13, 2013 09:27 EDT ENDP Endo Health downgraded to Market Perform from Outperform at William Blair 09:25 EDT ENDP On The Fly: Pre-market Movers Subscribe for More Information 09:04 EDT ENDP Endo Health falls 4.8% Endo Health is down 4.8%, or $1.67, to $33.30 08:13 EDT ENDP Endo Health price target lowered to $31 from $35 at Susquehanna Subscribe for More Information 07:49 EDT ENDP FDA decision on Opana a modest positive for Impax, says Leerink Leerink views the FDA's denial of Endo's (ENDP) Citizen Petition as a modest positive for Impax (IPXL), which it notes is the sole holder of 180 day exclusivity on generic Opana. However, Leerink says upside for Impax will be limited as Actavis (ACT), Sandoz, and Teva (TEVA) have settlements to enter the market starting in June 2013 when Impax's 180-day generic exclusivity expires. 07:45 EDT ENDP Endo Health price target lowered to $36 from $42 at Stifel Subscribe for More Information 07:32 EDT ENDP Endo Health downgraded to Sell from Neutral at Lazard Capital Subscribe for More Information 07:20 EDT ENDP Endo Health price target lowered to $37 from $47 at Jefferies Jefferies lowered its price target for Endo Health after the FDA ruled that crushable Opana generics can come to market. The firm keeps a Buy rating on the stock, saying the company's spending flexibility is underappreciated. 06:48 EDT ENDP Endo Health downgraded to Fair Value from Buy at CRT Capital Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.